Intensity Therapeutics (INTS) Return on Capital Employed (QoQ) (2023 - 2026)
Intensity Therapeutics (INTS) Return on Capital Employed (QoQ) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Intensity Therapeutics | 12.56 Mn | 12.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,749.00 |
| Mar 31, 2026 | 2,209.00 |
| Dec 31, 2025 | 13,055.00 |
| Sep 30, 2025 | 55,555.00 |
| Jun 30, 2025 | 36,697.00 |
| Mar 31, 2025 | -66,512.00 |
| Dec 31, 2024 | -14,967.00 |
| Sep 30, 2024 | -14,835.00 |
| Jun 30, 2024 | -11,765.00 |
| Mar 31, 2024 | -3,223.00 |
| Dec 31, 2023 | -2,518.00 |